Back to top
more

Range Cancer Therapeutics ETF: (CNCR)

(Delayed Data from NASDAQ) As of Jul 22, 2024 10:20 AM ET

$14.56 USD

14.56
280

+0.05 (0.35%)

Volume: 280

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

2 - Buy of 5   2      

Zacks News

Sweta Jaiswal, FRM headshot

Moderna ETFs to Gain on New Positive COVID-19 Vaccine Data

Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.

Sweta Jaiswal, FRM headshot

Moderna ETFs to Shine on U.S. Contracts for Coronavirus Vaccine

Moderna has inked a $1.5-billion coronavirus vaccine supply agreement with the U.S. government.

Sweta Killa headshot

Moderna Turns Red Hot: Biotech ETFs to Bet On

Moderna skyrocketed 245% since it announced its COVID-19 vaccine candidate mRNA-1273 on Feb 10. The solid run is likely to continue as most of the analysts are optimistic on the stock.

Sweta Jaiswal, FRM headshot

Moderna Inches Closer to Coronavirus Vaccine: ETFs to Shine

Moderna plans to begin the Phase 3 study of mRNA-1273 this month.

Sweta Killa headshot

How to Tap Red-Hot Moderna Stock With ETFs

Moderna shares have surged more than 280% so far this year on the positive development of coronavirus vaccine.

Sweta Jaiswal, FRM headshot

Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain

Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.

Sanghamitra Saha headshot

Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up

Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.

Sweta Jaiswal, FRM headshot

Is Moderna Winning the COVID-19 Vaccine Race? ETFs to Gain

Moderna has presented positive interim data from a phase I study evaluating its mRNA-based coronavirus vaccine candidate.

Sweta Jaiswal, FRM headshot

Biotech ETFs to Gain From Latest Advancements in Cancer Drugs

The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.

Sanghamitra Saha headshot

Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

Sanghamitra Saha headshot

4 Top Sectors of Last Week & Their Winning ETFs

These sectors topped last week and beat the broader market in a sweeping move.

Sanghamitra Saha headshot

Coronavirus Scare Supports These Biotech ETFs & Stocks

Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.

Sweta Killa headshot

Biotech Leading in Q4: Best ETFs & Stocks

We highlight five biotech ETFs and stocks that are leading the market in Q4.

Sanghamitra Saha headshot

Will Biotech ETFs Excel in Election Year Post a Surge in 2019?

Can biotech ETFs repeat its success story of 2019 in the election year of 2020?

Sweta Killa headshot

Biotech ETFs Hit New Highs on Deal Activities

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Sweta Jaiswal, FRM headshot

A Guide to Biotech ETF Investing

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.

Sweta Killa headshot

Biotech Tops in November: Best ETFs & Stocks

The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

Sweta Killa headshot

Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD

Healthcare bounced back with an outperformance starting the fourth quarter.

Sanghamitra Saha headshot

Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

Neena Mishra headshot

Cancer-Fighting Stocks & ETF: What You Need to Know

Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference

Neena Mishra headshot

Why Cancer-Fighting Stocks & ETFs Are Soaring

The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

Sweta Killa headshot

Trump Proposes 2020 Budget: ETFs to Top & Flop

Here are the key takeaways from the proposed 2020 budget and their expected impact on ETFs.

Sweta Killa headshot

Best and Worst ETFs of Last Week

After a solid comeback, the momentum on the Wall Street cooled down last week given the round of dismal data across the globe, the European Central Bank's surprise move and dismal U.S. jobs data that renewed threats of global slowdown.

Neena Mishra headshot

Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy

2018 Nobel Prize for medicine was awarded for immunotherapy research. Here is what investors need to know about stocks and ETF focused on this innovative area.

Neena Mishra headshot

Why These Small Cap Biotech ETFs are Soaring

These biotech ETFs have surged this year thanks mainly to tax reform, rising M&A and positive regulatory backdrop.